European Society of Cardiology (ESC) Congress 2025

Celebrating 75 years of the European Society of Cardiology, more than 33,000 participants and nearly 6,400 faculty and presenters came together at ESC 2025 in Madrid, Spain (29 August-1 September 2025), to discuss recent advances in clinical and scientific understanding of cardiovascular disease, including updated guidance on dyslipidaemia management, and a wealth of new data […]

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) have revised their recommendations on the use of omega-3 polyunsaturated fatty acids (PUFA) for TG lowering and added the apoC3 inhibitor, volanesorsen, as a possible treatment option for patients with familial chylomicronaemia syndrome (FCS).1

Full results of the ESSENCE–TIMI 73b trial of olezarsen in 1,349 patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL, median 238.5 mg/dL) and elevated cardiovascular (CV) risk, presented at the congress and published simultaneously in the New England Journal of Medicine, have reinforced the topline efficacy and safety data reported earlier this […]

Open label extension (OLE) data from the PALISADE trial of plozasiran in genetic or clinical familial chylomicronaemia syndrome (FCS) and the ARCHES-2 trial of zodasiran in mixed hyperlipidaemia have confirmed the efficacy and safety profiles of the two agents.

ANGPTL3 may be associated with plaque calcification in patients with coronary artery disease (CAD), and ANGPTL3 measurement may guide physicians in estimating the severity of plaque calcification and in planning anti-atherosclerotic management.

The GalNAc-conjugated apoC3 siRNA, RBD5044, has demonstrated favourable safety, predictable pharmacokinetic (PK), and durable pharmacodynamic (PD) effects in a first-in-human study.